MedTrace Logo

Phase I Study to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of HM781-36B in Patients With Advanced Solid Tumors

NCT01455571 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2014-02-26

No results posted yet for this study

Summary

The main objective of this study is to determine the maximum tolerated dose (MTD) of HM781-36B.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

HM781-36B

Q1DX14/2W for 3W HM781-36B

Sponsors & Collaborators

  • Seoul National University

    collaborator OTHER

  • Hanmi Pharmaceutical Company Limited

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2013-01-31
Completion
2013-01-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01455571 on ClinicalTrials.gov